We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Safety Committee Recommends Stopping Infusions of HES Solutions, Launches Review of Janus Kinase Inhibitors
EMA Safety Committee Recommends Stopping Infusions of HES Solutions, Launches Review of Janus Kinase Inhibitors
The European Medicines Agency’s (EMA) safety committee has recommended that the EU suspend authorizations for hydroxyethyl-starch (HES) solutions for infusion after concluding that the products are being administered in a potentially harmful manner.